LIMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liminatus Pharma Inc (LIMN) is not a strong buy at this time for a beginner investor with a long-term focus. The lack of positive financial performance, absence of news catalysts, and neutral trading sentiment do not support a compelling investment case. Additionally, technical indicators do not suggest a strong entry point, and there are no proprietary trading signals to prioritize this stock.
The MACD is positive but contracting, RSI is neutral at 46.595, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 0.208, with key resistance at 0.234 and support at 0.182. Overall, the technical indicators suggest a neutral outlook.
NULL identified. There is no recent news or significant trading activity from hedge funds, insiders, or Congress.
The stock has a 70% chance of declining in the next day (-1.18%), week (-0.52%), and month (-6.21%). Financial performance shows significant losses, with no revenue and negative EPS.
In Q4 2025, the company reported no revenue growth, a net income loss of -$8,168,927 (up 3467.22% YoY), and an EPS of -0.48 (up 4700.00% YoY). Gross margin remains at 0%. The financials indicate poor performance with no clear growth trends.
No analyst rating or price target changes available.
